Vita Nova Insights,^SM LLC to Provide Real-World Evidence, Platform Solutions & Analytics Support for Accelerating Improvements in Cancer Therapy Development & Patient Outcomes

FORT MYERS, Fla., March 27, 2024 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) today announced the formation of a new healthcare analytics subsidiary. This new entity, named Vita Nova Insights, LLC d/b/a Vita Nova Insights,^SM is wholly owned by Community Oncology Revitalization Enterprise, LLC (Core Ventures), FCS’ management services organization, and was created to serve as a precision oncology insights and real-world evidence platform. By partnering with FCS to advance oncology research through the development of unique proprietary datasets combining advanced data curation, data science, artificial intelligence, and data analysis capabilities, Vita Nova Insights is positioned to bring differentiated insights to the marketplace.

Over the past twelve months, the Vita Nova Insights team has successfully conducted over a dozen real-world evidence studies in collaboration with many of the world’s leading pharmaceutical companies. One of the compelling advantages of FCS’ real-world evidence program is the robust connection with physicians. This provides a means to not only identify challenges with certain therapies but also the ability to efficiently act on those opportunities to improve patient care.

“Healthcare analytics companies aren’t new, ” said FCS Chief Executive Officer Nathan H. Walcker. “But Vita Nova Insights is unique in its ability to symbiotically partner with FCS and its more than 250 providers across the state of Florida to study the efficacy of oncology treatment protocols and deliver perspectives from the clinic that directly inform clinical decisions and impact patient care downstream. Formally organizing our efforts with Vita Nova Insights cements our deep commitment to oncology research and further reflects our collective ability to generate real-world evidence that truly enables the discovery, development, and optimization of new therapeutic products. This platform is unmatched – harmonizing analytics talent, deep and clinically rich longitudinal datasets, and a market-leading independent community oncology group. There’s nothing out there like it,” Walcker concluded.

In collaboration with FCS, the new company supports physicians and clinical researchers’ access to the diversified data assets at FCS, including EMR, practice management, genomics, oral oncolytic pharmacy, laboratory, radiology, and radiation oncology systems. Information gleaned from our experience caring for over one million patients is standardized against industry reference data and further enriched using external data sources to create a more comprehensive picture of the health of every patient. Vita Nova Insights utilizes industry-leading data science, artificial intelligence, and its clinical oncology expertise to generate insights that help optimize patient care, enable clinical research, and convert FCS’ real-world data into the real-world evidence needed for the discovery and development of new therapies.

President & Managing Physician Lucio N. Gordan, MD added, “The advances we have been able to achieve in data aggregation, curation, and analysis over the past three years have put meaningful data literally at physicians’ fingertips, enabled precision-oncology decision support and provided clinical insights that enable us to be more nimble, more efficient in delivering superior patient care and cutting-edge therapies across the entire practice.”

Vita Nova Insights provides FCS physicians with analytic insights into all next-generation sequencing tests performed across the practice through an in-house service branded MolecularHelp^SM powered by the FCS PRECISE^SM precision-oncology platform.

“Given the pace of innovation in precision-oncology, with new therapies coming to market at a rate never seen before, it is challenging for physicians to keep up.” said Senior Vice President & Data Officer Trevor W. Heritage, PhD, “Vita Nova Insights analyses every genomics test result, in the context of the full patient clinical record, and alerts physicians to corresponding treatment options and associated evidence in real-time,” he concluded.

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the National Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Celebrating its 40^th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies, and advanced treatments, including targeted therapies genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians, and staff.

*Before approval

About Core Ventures
Community Oncology Revitalization Enterprise Ventures, L.L.C.,(Core Ventures) a physician-owned management services organization, provides operational and advisory support services to the nearly 100 FCS clinics throughout the state of Florida. 

Core Ventures helps align the varied practice locations, ancillary services, and patient care across FCS service lines by providing efficient and effective enterprise-wide management services.

View original content to download multimedia:https://www.prnewswire.com/news-releases/florida-cancer-specialists–research-institute-announces-formation-of-healthcare-analytics-company-302101060.html

SOURCE Florida Cancer Specialists & Research Institute